Bicistronic Vector Expression of Recombinant Jararhagin-C and Its Effects on Endothelial Cells DOI Creative Commons
Karla Fernanda Ferraz, Lhiri Hanna De Lucca Caetano,

Daniele Pereira Orefice

et al.

Toxins, Journal Year: 2024, Volume and Issue: 16(12), P. 524 - 524

Published: Dec. 3, 2024

Jararhagin-C (JarC) is a protein from the venom of Bothrops jararaca consisting disintegrin-like and cysteine-rich domains. JarC shows modulating effect on angiogenesis remodeling extracellular matrix constituents, improving wound healing in mouse experimental model. purified crude venom, yield less than 1%. The aim this work was to obtain recombinant form test its biological activity. For purpose, bicistronic vector pSUMOUlp1 used. This allowed expression toxin (rJarC) fusion with small ubiquitin-related modifier (SUMO) as well SUMO protease Ulp1. After expression, able efficiently remove rJarC inside bacteria. free at expected molecular mass recognized by polyclonal anti-jararhagin antibodies. In terms activity, both native forms showed no toxicity HUVEC cell line CRL1730 were effective migration activity vitro These results demonstrate successful production preservation which may facilitate further investigations into therapeutic potential snake venom-derived protein.

Language: Английский

Metabolomics and proteomics: synergistic tools for understanding snake venom inhibition DOI
S. Hussain, Danie Kingsley

Archives of Toxicology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 6, 2025

Language: Английский

Citations

0
The application of snake venom in anticancer drug discovery: an overview of the latest developments DOI

J. R. da Silva,

Juliana Castro-Amorim, Ashis K. Mukherjee

et al.

Expert Opinion on Drug Discovery, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 19

Published: Feb. 26, 2025

Snake venom is a rich source of toxins with great potential for therapeutic applications. In addition to its efficacy in treating hypertension, acute coronary syndrome, and other heart conditions, research has shown that this potent enzymatic cocktail capable selectively targeting destroying cancer cells many cases while sparing healthy cells. The authors begin by acknowledging the emerging trends snake-derived targeted therapies battling cancer. An extensive literature review examining effects various snake on cell lines, highlighting specific hallmarks each toxin targets presented. Furthermore, emphasize artificial intelligence accelerating venom-based drug discovery treatment, showcasing several innovative software applications field. Research indicates promising treatment as discussed can specifically target Nevertheless, variations composition venoms, ethical issues, delivery barriers limit their development into effective therapies. Thus, advances biotechnology, molecular engineering, silico methods are crucial refinement venom-derived compounds, improving specificity, overcoming these challenges, ultimately enhancing therapy.

Language: Английский

Citations

0
Growth Inhibitory Peptides: A Potential Novel Therapeutic Approach to Cancer Treatment DOI

Aixin Wang,

Gerald J. Mizejewski,

Chengqi Zhang

et al.

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177554 - 177554

Published: March 1, 2025

Language: Английский

Citations

0
Macrovipera lebetinus obtusa Venom and Its Fractions Affect Human Dermal Microvascular Endothelial and Fibrosarcoma Cells DOI Open Access

Nariné Ghazaryan,

Lars van Werven,

Thomas Liepold

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3601 - 3601

Published: April 11, 2025

The venom of Macrovipera lebetinus obtusa (MLO) has remarkable properties that are hard to overlook. This venom's described 38 protein components work synergistically, forming complexes greatly enhance their combined effectiveness. Previous studies have shown both crude and one its components, obtustatin, can reduce sarcoma tumors by 50% 30%, respectively. Obtustatin, a member the short disintegrin family, inhibits angiogenic activity α1β1 integrin, adhesive receptor collagen IV. However, mechanisms greater efficacy compared isolated remain unclear. To investigate this, we propose an experimental explore certain low-molecular-weight MLO venom. Our in vitro tests on fibrosarcoma (HT-1080) cells using six fractions revealed cytotoxic fractions, which, through mass spectrometry, were identified as containing classes such dimeric disintegrins, acidic phospholipase A2, serine proteinases. Notably, these exhibited minimal toxicity human dermal microvascular endothelial (HDEC) cells, suggesting potential promising candidate for oncotherapy future.

Language: Английский

Citations

0
Structural and Functional Differences of Rhodostomin and Echistatin in Integrin Recognition and Biological Implications DOI
Yi‐Chun Chen, Chun‐Hao Huang,

Yao‐Tsung Chang

et al.

Proteins Structure Function and Bioinformatics, Journal Year: 2025, Volume and Issue: unknown

Published: May 2, 2025

ABSTRACT Rhodostomin (Rho) and Echistatin (Ech) are RGD‐containing disintegrins with different sizes, disulfide bond patterns, amino acid sequences in their RGD loops C‐termini. Cell adhesion analyzes showed that Rho exhibited a 5.2‐, 18.9‐, 2.2‐, 1.7‐fold lower inhibitory activity against integrins αvβ3, α5β1, αIIbβ3, αvβ5 comparison those of Ech. In contrast, an 8.8‐fold higher than Ech inhibiting integrin αvβ6. The swapping Ech's loop C‐terminal into cannot increase its integrins' activities. Interestingly, the mutation Rho's PRGDMP sequence YH caused 8.2‐fold Structural they have similar conformations regions. Molecular docking found not only but also region interacted integrins, showing is important for recognition. αvβ6 H68 residue D129 β6. α5β1 H44 Q191 β1. 78.5‐ 10.9‐fold activities HUVEC proliferation A375 melanoma cell migration Rho. These findings demonstrate pattern, loop, may cause functional differences. structural differences between support potential as scaffolds to design drugs targeting respective integrins.

Language: Английский

Citations

0
Sea Anemone Heteractis magnifica Toxin Hct-S3 Suppresses the Migration of Solid Ehrlich Adenocarcinoma Cells Inoculated into BALB/C Mice DOI

Aleksandra Pavlenko,

А. А. Климович, Ekaterina A. Yurchenko

et al.

Biochemistry (Moscow) Supplement Series B Biomedical Chemistry, Journal Year: 2024, Volume and Issue: 18(S1), P. S99 - S105

Published: Dec. 1, 2024

Language: Английский

Citations

0
Bicistronic Vector Expression of Recombinant Jararhagin-C and Its Effects on Endothelial Cells DOI Creative Commons
Karla Fernanda Ferraz, Lhiri Hanna De Lucca Caetano,

Daniele Pereira Orefice

et al.

Toxins, Journal Year: 2024, Volume and Issue: 16(12), P. 524 - 524

Published: Dec. 3, 2024

Jararhagin-C (JarC) is a protein from the venom of Bothrops jararaca consisting disintegrin-like and cysteine-rich domains. JarC shows modulating effect on angiogenesis remodeling extracellular matrix constituents, improving wound healing in mouse experimental model. purified crude venom, yield less than 1%. The aim this work was to obtain recombinant form test its biological activity. For purpose, bicistronic vector pSUMOUlp1 used. This allowed expression toxin (rJarC) fusion with small ubiquitin-related modifier (SUMO) as well SUMO protease Ulp1. After expression, able efficiently remove rJarC inside bacteria. free at expected molecular mass recognized by polyclonal anti-jararhagin antibodies. In terms activity, both native forms showed no toxicity HUVEC cell line CRL1730 were effective migration activity vitro These results demonstrate successful production preservation which may facilitate further investigations into therapeutic potential snake venom-derived protein.

Language: Английский

Citations

0